THERANOSTICS- NEUROENDOCRINE TUMOURS
Sawin CT, Becker DV. Radioiodine and the treatment of hyperthyroidism: The early history. Thyroid 1997;7:163-76.
Sharp SE, Trout AT, Weiss BD, et al. MIBG in neuroblastoma diagnostic imaging and therapy. Radiographics 2016;36:258-78.
Van den Wyngaert T, Strobel K, Kampen WU, et al. The EANM practice guidelines for bone scintigraphy. Eur J Nucl Med Mol Imaging 2016;43:1723-38.
Kunikowska J, Lewington V, Krolicki L. Optimizing somatostatin receptor imaging in patients with neuroendocrine tumors: The impact of 99mTc-HYNICTOC SPECT/SPECT/CT versus 68Ga-DOTATATE PET/CT upon clinical management. Clin Nucl Med 2017;42:905-11.
Dorff TB, Agarwal N. Bone-targeted therapies to reduce skeletal morbidity in prostate cancer. Asian J Androl 2018;20:215-20.
Lee DY, Li KC. Molecular theranostics: A primer for the imaging professional. AJR Am J Roentgenol 2011;197:318-24.
Oberg K. Molecular imaging radiotherapy: Theranostics for personalized patient management of neuroendocrine tumors (NETs). Theranostics 2012;2:448-58.
Kulkarni HR, Singh A, Baum RP. Advances in the diagnosis of neuroendocrine neoplasms. Semin Nucl Med 2016;46:395-404.
Kunikowska J, Pawlak D, Bąk MI, et al. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with90Y/177 Lu-DOTATATE in neuroendocrine tumors with respect to the primary location: A 10-year study. Ann Nucl Med 2017;31:347-56.
Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of177 Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med 2017;376:125-35.
Strosberg J, Wolin E, Chasen B, et al. Health-related quality of life in patients with progressive midgut neuroendocrine tumors treated with177 Lu-dotatate in the phase III NETTER-1 trial. J Clin Oncol 2018;36:2578-84.
Mittra ES. Neuroendocrine tumor therapy:177 Lu-DOTATATE. AJR Am J Roentgenol 2018;211:278-85.
Bodei L, Mueller-Brand J, Baum RP, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours Eur J Nucl Med Mol Imaging 2013;40:800-16.
Virgolini I, Decristoforo C, Haug A, et al. Current status of theranostics in prostate cancer. Eur J Nucl Med Mol Imaging 2018;45:471-95.
Hofman M, Violet J, Sandhu S, et al. High activity, pain reduction and low toxicity with lutetium-177 PSMA617 theranostics in metastatic castrate-resistant prostate cancer (mCRPC): Results of a phase II prospective trial. J Nucl Med 2018;59 Supplement 1:531.
Keek SA, Leijenaar RT, Jochems A, et al. A review on radiomics and the future of theranostics for patient selection in precision medicine. Br J Radiol 2018;91:20170926.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Authors retain copyright and grant the Journal of Cancer & Allied Specialties (JCAS) right-of-first publication. In addition, the work will be simultaneously licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International license. This license allows others to share the work in whole or part (for non-commercial purpose), with an acknowledgement of the work’s authorship and initial publication in JCAS.
Furthermore, authors are free to enter into separate contractual arrangements for the non-exclusive distribution of the journal’s published version of the work, with an acknowledgement of its initial publication in this journal.
Authors are permitted and encouraged to share their work online or in medical or scientific conferences prior to or during submission process.